Drug intelligence / Profile preview

PF-07836395

Development stage: Phase 1
Lead developer: Pfizer
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PF-07836395 is a self-amplifying RNA (saRNA) vaccine candidate developed by Pfizer for the prevention of influenza. As an saRNA vaccine, it utilizes a viral replicase (typically derived from an alphavirus) to enable the RNA to replicate itself within the host cell after administration. This mechanism is designed to produce higher and more sustained levels of the encoded influenza antigens compared to conventional mRNA vaccines, potentially allowing for lower doses while maintaining robust immunogenicity. PF-07836395 was evaluated in a Phase 1 dose-finding clinical trial (NCT05477134) to assess its safety, tolerability, and immunogenic profile in healthy adults.

Other names: PF-07836395PF07836395PF 07836395

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on PF-07836395.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07836395.

Explore the full profile